DEA Fixes Typo in Obscure Tramadol Variant Ban
Published Date: 10/9/2026
Rule
Summary
The DEA fixed a small mistake in their August 2026 rule that put O-desmethyltramadol and all its related forms into Schedule I, meaning it's now officially a highly controlled substance. This correction makes sure every version of the drug is covered, starting retroactively from August 12, 2026, through August 12, 2028. Anyone handling this drug should know it’s tightly regulated now, with no changes to fees but serious legal controls in place.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
O-desmethyltramadol placed in Schedule I
O-desmethyltramadol (O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1-hydroxycyclohexyl]phenol) is placed in Schedule I of the Controlled Substances Act. The placement is applicable beginning August 12, 2026; this correcting amendment is effective October 9, 2026, and remains in effect until August 12, 2028.
Correction adds all chemical variants
The amendment corrects 21 CFR 1308.11(h)(88) to explicitly include O-desmethyltramadol's isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever those variants are possible, ensuring those chemical forms are also controlled. This corrected language applies beginning August 12, 2026 and the correction is effective October 9, 2026 through August 12, 2028.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
Previous / Next Documents
Previous: 2026-20736, Air Plan Approval; Michigan; Clean Data Determination for the Berrien, MI and Muskegon, MI Areas for the 2015 Ozone Standards
Great news for folks in Berrien and Muskegon counties, Michigan! The EPA says these areas have cleaned up their air enough to meet the 2015 ozone standards. Because of this, they don’t have to submit extra air quality plans or controls for now, saving time and effort as long as the air stays clean.
Next: 2026-20757, Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
The DEA is removing the special exemption for certain inactive butalbital prescription products that are no longer made or sold. Starting November 9, 2026, these products won’t be treated as exempt under drug laws anymore, but active products stay the same. This change mainly affects drug companies and pharmacies handling these old products, with no new costs for active medicines.